Exercise on semaglutide isn't just allowed, it's written into the label. Wegovy, the semaglutide brand for weight management, is meant to be used "in combination with a reduced calorie diet and increased physical activity," and the label doesn't list exercise as an interaction. What changes is how a workout can feel: smaller meals, a few weeks of queasiness, some flat-energy days, and, for people also taking certain diabetes medicines, a real chance of low blood sugar.

Wegovy and exercise: what the label says

The current Wegovy prescribing information (Revised: 6/2026) puts that diet-and-activity phrase in front of every weight and heart-risk use it lists. Ozempic, the diabetes brand of the same molecule, is labeled "as an adjunct to diet and exercise" for blood-sugar control in type 2 diabetes (Ozempic label, Revised: 5/2026).

That wording comes from how the trials were run. In the main weight trials, everyone, on drug or placebo, got counseling toward eating about 500 calories a day below their needs and at least 150 minutes of activity a week, starting with the first dose. In STEP 1, a 68-week trial of 1,961 adults without diabetes, average weight fell 14.9% on semaglutide and 2.4% on placebo (Wilding et al., New England Journal of Medicine 2021).

So those results describe semaglutide plus that support, and the trials never compared one workout with another.

Working out on semaglutide while the dose is rising

The label says stomach side effects were reported most often while the dose was being stepped up. In Wegovy's weight trials, fatigue or weakness was reported by 11% of people on semaglutide and 5% on placebo, dizziness by 8% and 4%, and nausea by 44% and 16%. Most people didn't feel tired, but low-energy days are real; does semaglutide make you tired sorts through the likely causes.

Two label points matter most around exercise:

  • Fluids. The label describes acute kidney injury, mostly in people whose nausea, vomiting or diarrhea left them dehydrated, and says kidney function should be watched in people with those symptoms, especially when starting or raising the dose. Sweat adds to fluid loss. The label doesn't say exercise harms the kidneys; the concern is running dry on top of a stomach upset.
  • Low blood sugar. The risk rises when semaglutide is combined with insulin or a sulfonylurea (a diabetes pill that pushes the pancreas to release insulin). Without them it's uncommon but not zero: a heart-outcomes trial of about 8,800 people per group without type 2 diabetes recorded 3 serious episodes on semaglutide and 1 on placebo. A long workout also draws on blood sugar, which is why a provider asks about both.

What the trials say about exercise on semaglutide

Losing weight doesn't automatically mean moving more. In Fitbit data from 753 adults with obesity who started a GLP-1 medicine, presented at the Endocrine Society's ENDO 2026 meeting on June 13, 2026, daily steps fell from about 5,047 to 4,487 and moderate-to-vigorous activity from 28 to 22 minutes a day (Endocrine Society). It looked back at records and covered several GLP-1 medicines.

No large trial has yet randomly assigned people on semaglutide to exercise or not and published results. The best controlled evidence uses liraglutide, an older, once-daily cousin in the same drug family.

That trial, S-LiTE, took 195 adults who had just lost about 13 kg (29 lb) on an eight-week low-calorie diet and split them into four groups for a year. Compared with placebo, the exercise-plus-liraglutide group ended 9.5 kg lighter, against 6.8 kg for liraglutide alone and 4.1 kg for exercise alone (Lundgren et al., New England Journal of Medicine 2021). The gap between the combination and liraglutide alone wasn't statistically clear. What stood out was body-fat percentage, which fell about twice as much with the combination, and fitness, which improved only in the combination group.

A year after all treatment stopped, people who'd only had liraglutide regained about 6 kg more than those who'd only exercised (Jensen et al., eClinicalMedicine 2024), which fits what's known about stopping semaglutide. A January 2026 analysis added that both exercise groups, typically logging about 116 minutes a week, climbed stairs faster and had better aerobic fitness than people on liraglutide alone (Jensen et al., Sports Medicine 2026).

As of September 22, 2026, the day this article was written, the newest pooled look is a network meta-analysis (a study that compares many trials at once) published online July 13, 2026. Across nine randomized trials and 1,009 adults, a GLP-1 medicine plus structured exercise was linked to the largest drops in weight and fat mass, more than either alone (Vandoni et al., Obesity Reviews 2026).

Strength training on semaglutide and lean mass

When weight comes off, some of it isn't fat. Scans call that part lean mass: everything that isn't fat or bone. It includes muscle, but also water, organs, skin and connective tissue, so lean mass and muscle aren't the same thing.

In a 140-person scan substudy of STEP 1, fat mass fell 19.3% and lean mass 9.7% on semaglutide. Because fat fell faster, lean mass ended up a bigger share of the body, up 3.0 percentage points (Wilding et al., Journal of the Endocrine Society 2021). The fuller picture is in does semaglutide cause muscle loss.

Strength is a separate measure. In SEMALEAN, a French study of 106 people on semaglutide 2.4 mg for a year, grip strength rose by 4.5 kg on average, while lean mass dipped about 3 kg over seven months and then held (Alissou et al., Diabetes, Obesity and Metabolism 2026). As of September 22, 2026, the day this article was written, the newest semaglutide study to report strength, published online August 25, 2026, found grip strength held steady over a year in 44 patients at a Barcelona obesity clinic, even as estimated skeletal muscle fell from 29.9 to 28.7 kg (Filippi-Arriaga et al., Obesity Facts 2026). Neither study was randomized or built to test exercise, so neither shows what strength training adds.

A trial built to answer that, LEAN-PREP in Kuwait, is enrolling 232 adults starting semaglutide or tirzepatide and assigning them to home resistance exercise, extra protein, both, or neither, with a thigh-muscle MRI at six months as the main measure (trial protocol, BMJ Open 2026). Its registry entry doesn't expect main data collection to finish until August 2029.

For all adults, the Physical Activity Guidelines for Americans say adults need 150 to 300 minutes a week of moderate aerobic activity, like brisk walking, plus muscle-strengthening activity at least two days a week (HHS). People weighing tirzepatide instead will find its own trial data in exercise on tirzepatide.

How a provider fits activity into the plan

Activity questions at intake aren't a fitness test. A provider wants the starting point: how active someone is now, joint or back limits, heart or kidney conditions, dizziness, recent vomiting or diarrhea, and every diabetes medicine. Those shape how a provider reads a symptom like light-headedness during a workout. The prescriber sets the actual dose.

Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor. A licensed provider reviews every request, and not everyone qualifies.

What the evidence supports so far

Movement was part of the semaglutide trials from the first dose. The closest randomized evidence links a GLP-1 medicine plus planned exercise to better fitness and body-fat balance than the medicine alone, and two semaglutide studies found grip strength held or rose. No study has yet shown a best workout for people on semaglutide. The useful plan fits the current dose, the other medicines involved and the body doing the work, and gets revisited as the dose changes.